Anne Komé, PharmD, explains that diabetes drug development is shifting to concurrent testing of metabolic effects.
Anne Komé, PharmD
Advertisement
Anne Komé, PharmD, CPP, BCACP, CDCES, is a clinical pharmacist practitioner in the Endocrinology Clinic at the UNC Chapel Hill Medical Center.
Articles by Anne Komé, PharmD
ADA 2026 research showed how oral ketones, irisin, and SGLT2 inhibitors may reveal new metabolic pathways beyond glucose control.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
2
GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis
3
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
4
Childhood Influenza Vaccine Rates Decreased From 2017 to 2023
5